These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22043053)

  • 1. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment.
    Li SP; Padhani AR; Makris A
    J Natl Cancer Inst Monogr; 2011; 2011(43):103-7. PubMed ID: 22043053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.
    Knopp MV; Brix G; Junkermann HJ; Sinn HP
    Magn Reson Imaging Clin N Am; 1994 Nov; 2(4):633-58. PubMed ID: 7489314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study.
    Jiang L; Weatherall PT; McColl RW; Tripathy D; Mason RP
    J Magn Reson Imaging; 2013 May; 37(5):1083-92. PubMed ID: 23124705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of dynamic contrast-enhanced magnetic resonance imaging in evaluating clinical responses to neoadjuvant chemotherapy in breast cancer.
    Liu YH; Ye JM; Xu L; Huang QY; Zhao JX; Duan XN; Qin NS; Wang XY
    Chin Med J (Engl); 2011 Jan; 124(2):194-8. PubMed ID: 21362364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
    Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
    Wu LM; Hu JN; Gu HY; Hua J; Chen J; Xu JR
    Breast Cancer Res Treat; 2012 Aug; 135(1):17-28. PubMed ID: 22476850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 13. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy.
    Hylton N
    Magn Reson Imaging Clin N Am; 2006 Aug; 14(3):383-9, vii. PubMed ID: 17098179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Locally advanced breast cancer (methods of treatment)].
    Portnoĭ SM
    Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923
    [No Abstract]   [Full Text] [Related]  

  • 16. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
    Ferretti S; Allegrini PR; O'Reilly T; Schnell C; Stumm M; Wartmann M; Wood J; McSheehy PM
    Clin Cancer Res; 2005 Nov; 11(21):7773-84. PubMed ID: 16278399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
    Atkin G; Taylor NJ; Daley FM; Stirling JJ; Richman P; Glynne-Jones R; d'Arcy JA; Collins DJ; Padhani AR
    Br J Surg; 2006 Aug; 93(8):992-1000. PubMed ID: 16673354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?
    Heldahl MG; Lundgren S; Jensen LR; Gribbestad IS; Bathen TF
    J Magn Reson Imaging; 2011 Sep; 34(3):547-56. PubMed ID: 21761463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unenhanced MRI at 3T in neo-adjuvant chemotherapy.
    Pediconi F; Vasselli F; Roselli A; Zaccagna F; Di Mare L; Catalano C
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S121-3. PubMed ID: 23083556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.